PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Negative EBIT growth while AVXL is at 7.38%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.64%
Negative operating income growth while AVXL is at 7.38%. Joel Greenblatt would press for urgent turnaround measures.
-15.16%
Negative net income growth while AVXL stands at 8.04%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
2.78%
EPS growth under 50% of AVXL's 15.64%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.78%
Diluted EPS growth under 50% of AVXL's 15.64%. Michael Burry would worry about an eroding competitive position or excessive dilution.
19.07%
Share count expansion well above AVXL's 8.78%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
19.07%
Diluted share count expanding well above AVXL's 8.78%. Michael Burry would fear significant dilution to existing owners' stakes.
-16.01%
Dividend reduction while AVXL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-30.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Negative 10Y OCF/share CAGR while AVXL stands at 64.52%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.33%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
68.32%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-1414.90%
Negative 10Y net income/share CAGR while AVXL is at 79.83%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.17%
5Y net income/share CAGR above 1.5x AVXL's 41.16%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
80.18%
3Y net income/share CAGR above 1.5x AVXL's 23.81%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1411.37%
10Y equity/share CAGR above 1.5x AVXL's 186.82%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-77.60%
Negative 5Y equity/share growth while AVXL is at 12.35%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-28.05%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Asset growth above 1.5x AVXL's 9.21%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
13.37%
BV/share growth above 1.5x AVXL's 1.45%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-15.85%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
22.47%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-1.59%
We cut SG&A while AVXL invests at 1.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.